<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02767609</url>
  </required_header>
  <id_info>
    <org_study_id>5140083</org_study_id>
    <nct_id>NCT02767609</nct_id>
  </id_info>
  <brief_title>Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging</brief_title>
  <official_title>Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test a new MRI sequence that measures cerebral blood flow (CBF). Because this
      technique for measuring CBF is new, there is little information on what the normal values for
      different regions of the brain should be. Information from the study will be used to
      establish normative CBF values for the brain, improving the reliable use of this technique
      for the diagnosis of brain injury or disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cerebral blood flow (CBF) represents an important physiological parameter for the diagnosis
      and management of multiple brain disorders. The clinical need for CBF measurements is further
      complicated by the desire to have a non-invasive method with high temporal resolution that
      can measure CBF over a wide range of blood flows and in a wide range of patients. Numerous
      techniques are available to measure CBF. Nuclear medicine approaches, such as single positron
      emission computed tomography (SPECT) and positron emission tomography (PET) rely on
      radioisotopes which can be problematic in the pediatric population. In contrast, MRI-based
      methods are non-invasive and the CBF information can be obtained in conjunction with other
      MRI techniques (i.e. diffusion weighted imaging or spectroscopy) which allows for a combined
      longitudinal assessment of CBF, morphology, and metabolism, to provide a more complete
      understanding of the developing pathophysiological mechanisms.

      Arterial spin labeling (ASL) perfusion imaging uses arterial blood water as an endogenous
      diffusible tracer where radiofrequency (RF) pulses magnetically label the moving spins in
      flowing blood without the use of a contrast agent. After a time delay allowing for the
      magnetically labeled blow to flow into the brain, &quot;labeled&quot; images are acquired. Separate
      control images are also acquired, without labeling and the difference between the two sets of
      imaged provides a measure of perfusion. Since gadolinium-based contrast agents are not
      required, the ASL perfusion technique is completely non-invasive. In addition, ASL techniques
      are insensitive to blood-brain barrier permeability changes, which can occur after strokes or
      with tumors.

      Because gadolinium-based contrast is not used, the ASL technique has an inherently lower
      sensitivity than DSC-PWI. To date, there are a number of commercially available ASL
      techniques that differ in their labeling schemes, which has contributed to the difficulty in
      obtaining consistent results across different patient populations (pediatric, elderly,
      stroke, tumors). A number of recent reports using pseudo-continuous ASL (pCASL) have been
      published and show increased reliability across different patient populations. Moreover, a
      recent consensus statement published by the International Society of Magnetic Resonance in
      Medicine Perfusion Study Group recommends the use of pCASL labeling strategies for clinical
      applications.

      The objectives of this study is to determine the accuracy and reliability of a newly
      developed pCASL sequence and post-processing software across multiple patient populations
      (neonate to elderly) and pathological processes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">March 3, 2017</completion_date>
  <primary_completion_date type="Actual">March 3, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regional Cerebral Blood Flow Values of the Brain Measured Using Pseudo-continuous Arterial Spin Labeling (pCASL) MRI.</measure>
    <time_frame>single encounter</time_frame>
    <description>The relative cerebral blood flow (CBF) in frontal, parietal, occipital gray matter and white matter regions, basal ganglia, thalami, and cerebellum will be measured using region of interest analysis to determine institutional normative values for healthy subjects.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Alzheimer's Disease</condition>
  <condition>Tumor</condition>
  <arm_group>
    <arm_group_label>Magentic Resonance Imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>magnetic Resonance Imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.</description>
    <arm_group_label>Magentic Resonance Imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any person between the ages of 18-90 years, who is undergoing routine magnetic
             resonance imaging (MRI) of the head with or without contrast at Loma Linda University
             Medical Center.

          -  Must be eligible for MRI (no electronic or metal implants that are not MR compatible).

        Exclusion Criteria:

          -  Electronic or metal implant that is not MRI safe, pregnancy or claustrophobia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda Bartnik Olson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University Medical Center</affiliation>
  </overall_official>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <results_first_submitted>February 26, 2019</results_first_submitted>
  <results_first_submitted_qc>April 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2019</results_first_posted>
  <last_update_submitted>April 9, 2019</last_update_submitted>
  <last_update_submitted_qc>April 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Brenda Bartnik Olson, PhD</investigator_full_name>
    <investigator_title>Associate Proffesor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT02767609/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 28, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT02767609/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Magentic Resonance Imaging</title>
          <description>Magnetic Resonance Imaging.
Magnetic Resonance Imaging: All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>any person between age of 18-90</population>
      <group_list>
        <group group_id="B1">
          <title>Magentic Resonance Imaging</title>
          <description>Magnetic Resonance Imaging.
Magnetic Resonance Imaging: All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Regional Cerebral Blood Flow Values of the Brain Measured Using Pseudo-continuous Arterial Spin Labeling (pCASL) MRI.</title>
        <description>The relative cerebral blood flow (CBF) in frontal, parietal, occipital gray matter and white matter regions, basal ganglia, thalami, and cerebellum will be measured using region of interest analysis to determine institutional normative values for healthy subjects.</description>
        <time_frame>single encounter</time_frame>
        <population>control</population>
        <group_list>
          <group group_id="O1">
            <title>Magentic Resonance Imaging</title>
            <description>Magnetic Resonance Imaging.
Magnetic Resonance Imaging: All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Regional Cerebral Blood Flow Values of the Brain Measured Using Pseudo-continuous Arterial Spin Labeling (pCASL) MRI.</title>
          <description>The relative cerebral blood flow (CBF) in frontal, parietal, occipital gray matter and white matter regions, basal ganglia, thalami, and cerebellum will be measured using region of interest analysis to determine institutional normative values for healthy subjects.</description>
          <population>control</population>
          <units>ml/100g/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Magentic Resonance Imaging</title>
          <description>Magnetic Resonance Imaging.
Magnetic Resonance Imaging: All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brenda Bartnik Olson</name_or_title>
      <organization>Loma Linda University medical Center</organization>
      <phone>909-558-4000 ext 85216</phone>
      <email>bbartnik@llu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

